Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.41 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.41 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | SCN1A | P35498 | 1/20 | 0.38 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.38 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8592635 | 1.00 | SLC6A3 (0.47) | SLC6A3KMT2AADRB2ADRB1ADRB3 | |
| SCHEMBL9000849 | 0.86 | L3MBTL1 (0.47) | KMT2ALMNAALDH1A1KDM4EHTT | |
| SCHEMBL9000860 | 0.86 | L3MBTL1 (0.47) | KMT2ALMNAALDH1A1KDM4EHTT | |
| SCHEMBL3226833 | 0.82 | ESR1 (0.56) | KMT2AALDH1A1KDM4EESR1ESR2 | |
| SCHEMBL8594247 | 0.82 | TDP1 (0.47) | KMT2AADRB2ADRB1ADRB3LMNA | |
| SCHEMBL8594253 | 0.82 | TDP1 (0.47) | KMT2AADRB2ADRB1ADRB3LMNA | |
| SCHEMBL3012929 | 0.82 | ESR1 (0.56) | KMT2AALDH1A1KDM4EESR1ESR2 | |
| SCHEMBL3205350 | 0.82 | ESR1 (0.56) | KMT2AALDH1A1KDM4EESR1ESR2 | |
| SCHEMBL3526852 | 0.82 | ALDH1A1 (0.56) | SLC6A3KMT2AADRB2ADRB1ADRB3 | |
| SCHEMBL982864 | 0.81 | LMNA (0.55) | KMT2AADRB2ADRB1ADRB3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250302968-A1 | RADIATION CLEAVED DRUG-CONJUGATE LINKERS ENABLE LOCAL PAYLOAD RELEASE SCLEROSIS | THE GENERAL HOSPITAL CORPORATION | 2025-10-02 | — | — | US | disclosed |
| EP-4608453-A1 | EXATECAN-DERIVED ADC LINKER-PAYLOADS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | Merck Sharp & Dohme LLC (US) | 2025-09-03 | — | — | EP | disclosed |
| WO-2025078841-A2 | ANTIBODIES, CONJUGATES, AND USES THEREOF | ANTIKOR BIOPHARMA LIMITED (GB) | 2025-04-17 | — | — | WO | disclosed |
| EP-4522139-A1 | RADIATION CLEAVED DRUG-CONJUGATE LINKERS ENABLE LOCAL PAYLOAD RELEASE SCLEROSIS | The General Hospital Corporation (US) | 2025-03-19 | — | — | EP | disclosed |
| US-20240208987-A1 | EXATECAN-DERIVED ADC LINKER-PAYLOADS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240208987-A1 | EXATECAN-DERIVED ADC LINKER-PAYLOADS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240208987-A1 | EXATECAN-DERIVED ADC LINKER-PAYLOADS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2024-06-27 | — | — | US | disclosed |
| WO-2024091437-A1 | EXATECAN-DERIVED ADC LINKER-PAYLOADS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2024-05-02 | — | — | WO | disclosed |
| WO-2024091437-A1 | EXATECAN-DERIVED ADC LINKER-PAYLOADS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2024-05-02 | — | — | WO | disclosed |
| WO-2023220280-A1 | RADIATION CLEAVED DRUG-CONJUGATE LINKERS ENABLE LOCAL PAYLOAD RELEASE SCLEROSIS | THE GENERAL HOSPITAL CORPORATION (US) | 2023-11-16 | — | — | WO | disclosed |
| WO-2022093800-A2 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | ELUCIDA ONCOLOGY, INC. (US) | 2022-05-05 | — | — | WO | disclosed |
| WO-2022093800-A2 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | ELUCIDA ONCOLOGY, INC. (US) | 2022-05-05 | — | — | WO | disclosed |
| WO-2015038426-A1 | SELF-IMMOLATIVE LINKERS CONTAINING MANDELIC ACID DERIVATIVES, DRUG-LIGAND CONJUGATES FOR TARGETED THERAPIES AND USES THEREOF | ASANA BIOSCIENCES, LLC (US) | 2015-03-19 | — | — | WO | disclosed |
| WO-2015038426-A1 | SELF-IMMOLATIVE LINKERS CONTAINING MANDELIC ACID DERIVATIVES, DRUG-LIGAND CONJUGATES FOR TARGETED THERAPIES AND USES THEREOF | ASANA BIOSCIENCES, LLC (US) | 2015-03-19 | — | — | WO | disclosed |
| US-7799933-B2 | Sulfonamide derivatives | HOFFMAN-LA ROCHE INC. (US) | 2010-09-21 | — | — | US | disclosed |
| EP-2097373-B1 | SULFONAMIDE DERIVATIVES AS LIVER CARNITINE PALMITOYL TRANSFERASE (L-CPTL ) | HOFFMANN LA ROCHE (CH) | 2010-08-11 | — | — | EP | disclosed |
| EP-2097373-A1 | SULFONAMIDE DERIVATIVES AS LIVER CARNITINE PALMITOYL TRANSFERASE (L-CPTL ) | F. Hoffmann-Roche AG (CH) | 2009-09-09 | — | — | EP | disclosed |
| US-20080153805-A1 | SULFONAMIDE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2008-06-26 | — | — | US | disclosed |
| WO-2008074692-A1 | SULFONAMIDE DERIVATIVES AS LIVER CARNITINE PALMITOYL TRANSFERASE (L-CPTL ) | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-26 | — | — | WO | disclosed |
| EP-0816316-A1 | PROCESS FOR PRODUCING 1,2-ETHANEDIOL DERIVATIVES | NITTO CHEMICAL INDUSTRY CO., LTD. (JP) | 1998-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153805-A1 | SULFONAMIDE DERIVATIVES | CPT1A, SULT2A1, SULT1A1 | SLC6A3 634/4885KMT2A 2129/4885ADRB2 1505/4885 |
| US-20240208987-A1 | EXATECAN-DERIVED ADC LINKER-PAYLOADS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | ADCY3, ADCY8, ADCY7 | SLC6A3 694/4885KMT2A 1105/4885ADRB2 4208/4885 |
| US-20250302968-A1 | RADIATION CLEAVED DRUG-CONJUGATE LINKERS ENABLE LOCAL PAYLOAD RELEASE SCLEROSIS | HIF1A, HIF1AN, DCLRE1A | SLC6A3 3312/4885KMT2A 2082/4885ADRB2 3977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.